Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
ID: 359866Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359866
Timeline
    Description

    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)" aimed at advancing research on extracellular vesicles (EVs) as therapeutics in regenerative medicine. This cooperative agreement seeks to support the translation of EV-based therapeutics, focusing on their role in intercellular communication and potential applications in tissue repair and regeneration. Eligible applicants for this discretionary funding opportunity include small businesses, with no cost-sharing or matching requirements. Interested parties should note that the estimated synopsis post date is October 15, 2025, with a closing date of February 17, 2026, and an anticipated award date of December 17, 2026. For further inquiries, applicants can contact Christine Happel, Ph.D., at christine.happel@nih.gov or by phone at 240-472-7550.

    Point(s) of Contact
    Christine Happel, Ph.D. National Center for Advancing Translational Sciences (NCATS)
    (240) 472-7550
    christine.happel@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx)" through a cooperative agreement aimed at supporting the development of extramural Resource Centers (RCs) focused on tissue engineering and regenerative medicine (TE/RM). The initiative seeks to foster interdisciplinary translational projects (ITPs) that leverage clinical, scientific, and regulatory expertise to advance therapeutics, diagnostics, and monitoring solutions for tissue damage caused by various health conditions. This funding cycle is particularly significant as it aims to facilitate the validation and preclinical testing of promising TE/RM products, with the goal of achieving regulatory approvals for first-in-human studies. Interested applicants, particularly small businesses with relevant expertise, are encouraged to prepare for future applications, as the estimated synopsis post date is October 7, 2025, with a closing date of November 7, 2025, and an anticipated award date of July 1, 2026. For further inquiries, potential applicants can contact Dr. Scott Verbridge at scott.verbridge@nih.gov or by phone at 301-594-0676.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)" aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects that contribute to the field, although applications are not currently being solicited. With an estimated total program funding of $400,000, interested applicants should prepare for the upcoming Notice of Funding Opportunity (NOFO), with key dates including an estimated synopsis post date of August 1, 2025, and a close date of October 21, 2025. For further inquiries, potential applicants can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator- Initiated Studies (UH3 Clincical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies," aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects, although applications are not currently being solicited. The funding will be provided through a cooperative agreement, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 21, 2025. For further inquiries, interested parties can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Opportunities for Collaborative Research at the NIH Clinical Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Opportunities for Collaborative Research at the NIH Clinical Center," aimed at supporting collaborative translational research projects that enhance the application of basic biological discoveries to clinical settings. This program encourages partnerships between NIH intramural investigators and extramural researchers to accelerate patient-centric translational research, focusing on understanding disease processes and developing new therapeutic interventions, diagnostics, or prevention strategies. Interested small businesses can apply for this cooperative agreement, with no cost-sharing requirement, and should note that the estimated synopsis post date is September 1, 2025, with a closing date of December 12, 2025. For further inquiries, applicants can contact Dr. David J. Eckstein at 301-496-4121 or via email at ClinicalCtrPartner@mail.nih.gov.
    National Centers for Cryo-electron Tomography (cryoET)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "National Centers for Cryo-electron Tomography (cryoET)" aimed at supporting service centers that provide nationwide access to advanced cryo-electron tomography instrumentation and technical support. This program is designed to assist investigators in acquiring the necessary skills to conduct cryoET studies, which are crucial for advancing health-related research. Eligible applicants for this discretionary grant include small businesses, with no cost-sharing or matching requirements. Interested parties can reach out to Dr. Paula Flicker at flickerp@nigms.nih.gov or by phone at 240-274-7460 for further information. The estimated synopsis close date is January 26, 2026, with awards expected to be made by September 1, 2026.
    Selective Precision Targeting (SPoT)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled Selective Precision Targeting (SPoT) aimed at advancing therapeutic drug delivery systems to specific hard-to-reach locations within the human body. This initiative seeks to optimize the targeting of nanoparticle therapeutics, assess biodistribution and off-target effects, provide evidence of functional cargo activity, and determine the optimal route of administration using microphysiological systems. With an estimated total program funding of $1.5 million and the expectation of awarding five grants, eligible small businesses are encouraged to apply. Interested applicants can reach out to Dr. Passley Hargrove-Grimes at passley.hargrove@nih.gov or by phone at 240-485-4149, with proposals due by February 17, 2026, and project start anticipated on January 18, 2027.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening," aimed at developing and validating advanced 3-D tissue models for drug efficacy testing. This initiative seeks to create non-animal models that accurately mimic the physiological properties of human tissues, thereby enhancing the predictive accuracy of drug screening processes. With an estimated total program funding of $1,600,000 and the expectation of awarding two grants, interested applicants are encouraged to utilize the resources available at the NCATS 3-D Bioprinting laboratory. The application process is open to various eligible entities, excluding non-domestic applicants, with a submission deadline anticipated by June 16, 2026. For further inquiries, potential applicants can contact Dobrila D. Rudnicki, Ph.D., at dobrila.rudnicki@nih.gov or by phone at 240-535-6621.
    Forecast for Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the Blueprint MedTech Translator program, aimed at supporting small businesses in the development of innovative medical devices for the nervous and neuromuscular systems. This cooperative agreement will provide non-dilutive funding and additional resources to facilitate the translation of groundbreaking technologies from early-stage development to clinical studies, ultimately accelerating patient access to effective medical devices. Interested applicants should note that while applications are not currently being solicited, they are encouraged to begin forming collaborations and developing projects in anticipation of the NOFO, with an estimated synopsis posting date of July 21, 2025, and a closing date of October 20, 2025. For further inquiries, potential applicants can contact Nicholas Langhals, PhD, at Blueprint-MedTech@nih.gov or by phone at 301-435-0090.